# Napco Security Technologies, Inc: financial statements, quarterly NSSC · Nasdaq · CIK 69633 · [Technology](/sectors/technology.md) · fiscal year ends Jun 30 Pages: [Overview](/companies/nssc.md) · [Financials](/companies/nssc/financials.md) · [Filings](/companies/nssc/filings.md) · [Insiders](/companies/nssc/insiders.md) Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/nssc/financials.md?period=annual). ## Income statement | Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | period not labelled (2025-03-31) | Q4 FY2025 (2025-06-30) | Q3 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [41.7](/filings/0001558370-24-014247.md) | [47.5](/filings/0001558370-25-000601.md) | [49.3](/filings/0001558370-25-006267.md) | [50.3 d](/filings/0001104659-26-100081.md) | [44.0](/filings/0001104659-25-105434.md) | [42.9](/filings/0001104659-26-009130.md) | [44.0](/filings/0001104659-26-055383.md) | [50.7 d](/filings/0001104659-26-100081.md) | [49.2](/filings/0001104659-25-105434.md) | [48.2](/filings/0001104659-26-009130.md) | [49.2](/filings/0001104659-26-055383.md) | [55.8 d](/filings/0001104659-26-100081.md) | | Cost of revenue | $m | [19.3](/filings/0001558370-24-014247.md) | [22.5](/filings/0001558370-25-000601.md) | [22.8](/filings/0001558370-25-006267.md) | [22.5 d](/filings/0001104659-26-100081.md) | [19.4](/filings/0001104659-25-105434.md) | [18.4](/filings/0001104659-26-009130.md) | [18.8](/filings/0001104659-26-055383.md) | [23.9 d](/filings/0001104659-26-100081.md) | [21.3](/filings/0001104659-25-105434.md) | [19.9](/filings/0001104659-26-009130.md) | [19.7](/filings/0001104659-26-055383.md) | [21.6 d](/filings/0001104659-26-100081.md) | | Gross profit | $m | [22.4](/filings/0001558370-24-014247.md) | [25.0](/filings/0001558370-25-000601.md) | [26.5](/filings/0001558370-25-006267.md) | [27.8 d](/filings/0001104659-26-100081.md) | [24.6](/filings/0001104659-25-105434.md) | [24.5](/filings/0001104659-26-009130.md) | [25.1](/filings/0001104659-26-055383.md) | [26.8 d](/filings/0001104659-26-100081.md) | [27.8](/filings/0001104659-25-105434.md) | [28.2](/filings/0001104659-26-009130.md) | [29.5](/filings/0001104659-26-055383.md) | [34.2 d](/filings/0001104659-26-100081.md) | | Research and development | $m | [2.4](/filings/0001558370-24-014247.md) | [2.5](/filings/0001558370-25-000601.md) | [2.8](/filings/0001558370-25-006267.md) | [3.0 d](/filings/0001104659-26-100081.md) | [3.1](/filings/0001104659-25-105434.md) | [3.1](/filings/0001104659-26-009130.md) | [3.2](/filings/0001104659-26-055383.md) | [3.2 d](/filings/0001104659-26-100081.md) | [3.2](/filings/0001104659-25-105434.md) | [3.5](/filings/0001104659-26-009130.md) | [3.4](/filings/0001104659-26-055383.md) | [3.7 d](/filings/0001104659-26-100081.md) | | Selling, general and administrative | $m | [8.4](/filings/0001558370-24-014247.md) | [8.7](/filings/0001558370-25-000601.md) | [9.2](/filings/0001558370-25-006267.md) | [10.9 d](/filings/0001104659-26-100081.md) | [9.7](/filings/0001104659-25-105434.md) | [10.2](/filings/0001104659-26-009130.md) | [10.8](/filings/0001104659-26-055383.md) | [11.5 d](/filings/0001104659-26-100081.md) | [11.0](/filings/0001104659-25-105434.md) | [10.0](/filings/0001104659-26-009130.md) | [11.3](/filings/0001104659-26-055383.md) | [12.1 d](/filings/0001104659-26-100081.md) | | Operating income | $m | [11.6](/filings/0001558370-24-014247.md) | [13.8](/filings/0001558370-25-000601.md) | [14.5](/filings/0001558370-25-006267.md) | [14.0 d](/filings/0001104659-26-100081.md) | [11.9](/filings/0001104659-25-105434.md) | [11.2](/filings/0001104659-26-009130.md) | [11.1](/filings/0001104659-26-055383.md) | [12.1 d](/filings/0001104659-26-100081.md) | [13.6](/filings/0001104659-25-105434.md) | [14.8](/filings/0001104659-26-009130.md) | [(1.2)](/filings/0001104659-26-055383.md) | [18.4 d](/filings/0001104659-26-100081.md) | | Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Income tax | $m | [1.5](/filings/0001558370-24-014247.md) | [1.9](/filings/0001558370-25-000601.md) | [1.9](/filings/0001558370-25-006267.md) | [1.2 d](/filings/0001104659-26-100081.md) | [1.8](/filings/0001104659-25-105434.md) | [1.6](/filings/0001104659-26-009130.md) | [1.9](/filings/0001104659-26-055383.md) | [1.3 d](/filings/0001104659-26-100081.md) | [2.5](/filings/0001104659-25-105434.md) | [2.2](/filings/0001104659-26-009130.md) | [0.2](/filings/0001104659-26-055383.md) | [1.9 d](/filings/0001104659-26-100081.md) | | Net income | $m | [10.5](/filings/0001558370-25-006267.md) | [12.6](/filings/0001558370-25-006267.md) | [13.2](/filings/0001558370-25-006267.md) | [13.5 d](/filings/0001104659-26-100081.md) | [11.2](/filings/0001104659-26-055383.md) | [10.5](/filings/0001104659-26-055383.md) | [10.1](/filings/0001104659-26-055383.md) | [11.6 d](/filings/0001104659-26-100081.md) | [12.2](/filings/0001104659-26-055383.md) | [13.5](/filings/0001104659-26-055383.md) | [(0.4)](/filings/0001104659-26-055383.md) | [17.8 d](/filings/0001104659-26-100081.md) | | Diluted EPS | $ per share | [0.28](/filings/0001558370-24-014247.md) | [0.34](/filings/0001558370-25-000601.md) | [0.36](/filings/0001558370-25-006267.md) | not reported | [0.30](/filings/0001104659-25-105434.md) | [0.28](/filings/0001104659-26-009130.md) | [0.28](/filings/0001104659-26-055383.md) | not reported | [0.34](/filings/0001104659-25-105434.md) | [0.38](/filings/0001104659-26-009130.md) | [(0.01)](/filings/0001104659-26-055383.md) | not reported | | Basic EPS | $ per share | [0.28](/filings/0001558370-24-014247.md) | [0.34](/filings/0001558370-25-000601.md) | [0.36](/filings/0001558370-25-006267.md) | not reported | [0.30](/filings/0001104659-25-105434.md) | [0.29](/filings/0001104659-26-009130.md) | [0.28](/filings/0001104659-26-055383.md) | not reported | [0.34](/filings/0001104659-25-105434.md) | [0.38](/filings/0001104659-26-009130.md) | [(0.01)](/filings/0001104659-26-055383.md) | not reported | - Revenue: us-gaap:Revenues - Cost of revenue: us-gaap:CostOfGoodsAndServicesSold - Gross profit: us-gaap:GrossProfit - Research and development: us-gaap:ResearchAndDevelopmentExpense - Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense - Operating income: us-gaap:OperatingIncomeLoss - Interest expense: not reported - Income tax: us-gaap:IncomeTaxExpenseBenefit - Net income: us-gaap:NetIncomeLoss - Diluted EPS: us-gaap:EarningsPerShareDiluted - Basic EPS: us-gaap:EarningsPerShareBasic ## Balance sheet | Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | period not labelled (2025-03-31) | FY2025 (2025-06-30) | Q3 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Cash and equivalents | $m | [43.6](/filings/0001558370-23-018474.md) | [47.3](/filings/0001558370-24-000760.md) | [55.5](/filings/0001558370-24-006776.md) | [65.3](/filings/0001558370-25-011750.md) | [85.6](/filings/0001558370-24-014247.md) | [86.0](/filings/0001558370-25-000601.md) | [73.4](/filings/0001558370-25-006267.md) | [83.1](/filings/0001104659-26-100081.md) | [95.4](/filings/0001104659-25-105434.md) | [105](/filings/0001104659-26-009130.md) | [114](/filings/0001104659-26-055383.md) | [127](/filings/0001104659-26-100081.md) | | Current assets | $m | [138](/filings/0001558370-23-018474.md) | [150](/filings/0001558370-24-000760.md) | [158](/filings/0001558370-24-006776.md) | [169](/filings/0001558370-25-011750.md) | [171](/filings/0001558370-24-014247.md) | [165](/filings/0001558370-25-000601.md) | [152](/filings/0001558370-25-006267.md) | [162](/filings/0001104659-26-100081.md) | [173](/filings/0001104659-25-105434.md) | [181](/filings/0001104659-26-009130.md) | [193](/filings/0001104659-26-055383.md) | [208](/filings/0001104659-26-100081.md) | | Total assets | $m | [177](/filings/0001558370-23-018474.md) | [186](/filings/0001558370-24-000760.md) | [195](/filings/0001558370-24-006776.md) | [208](/filings/0001558370-25-011750.md) | [210](/filings/0001558370-24-014247.md) | [203](/filings/0001558370-25-000601.md) | [191](/filings/0001558370-25-006267.md) | [198](/filings/0001104659-26-100081.md) | [206](/filings/0001104659-25-105434.md) | [213](/filings/0001104659-26-009130.md) | [222](/filings/0001104659-26-055383.md) | [239](/filings/0001104659-26-100081.md) | | Current liabilities | $m | [21.9](/filings/0001558370-23-018474.md) | [21.2](/filings/0001558370-24-000760.md) | [19.9](/filings/0001558370-24-006776.md) | [22.2](/filings/0001558370-25-011750.md) | [24.7](/filings/0001558370-24-014247.md) | [21.8](/filings/0001558370-25-000601.md) | [22.6](/filings/0001558370-25-006267.md) | [24.1](/filings/0001104659-26-100081.md) | [24.5](/filings/0001104659-25-105434.md) | [22.7](/filings/0001104659-26-009130.md) | [39.0](/filings/0001104659-26-055383.md) | [42.5](/filings/0001104659-26-100081.md) | | Total liabilities | $m | [28.7](/filings/0001558370-23-018474.md) | [27.9](/filings/0001558370-24-000760.md) | [26.6](/filings/0001558370-24-006776.md) | [28.9](/filings/0001558370-25-011750.md) | [31.3](/filings/0001558370-24-014247.md) | [28.5](/filings/0001558370-25-000601.md) | [29.3](/filings/0001558370-25-006267.md) | [29.5](/filings/0001104659-26-100081.md) | [29.9](/filings/0001104659-25-105434.md) | [28.0](/filings/0001104659-26-009130.md) | [44.2](/filings/0001104659-26-055383.md) | [47.7](/filings/0001104659-26-100081.md) | | Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Shareholders' equity | $m | [148](/filings/0001558370-25-006267.md) | [158](/filings/0001558370-25-006267.md) | [168](/filings/0001558370-25-006267.md) | [179](/filings/0001104659-26-100081.md) | [179](/filings/0001104659-26-055383.md) | [174](/filings/0001104659-26-055383.md) | [162](/filings/0001104659-26-055383.md) | [169](/filings/0001104659-26-100081.md) | [176](/filings/0001104659-26-055383.md) | [185](/filings/0001104659-26-055383.md) | [178](/filings/0001104659-26-055383.md) | [191](/filings/0001104659-26-100081.md) | - Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue - Current assets: us-gaap:AssetsCurrent - Total assets: us-gaap:Assets - Current liabilities: us-gaap:LiabilitiesCurrent - Total liabilities: us-gaap:Liabilities - Long-term debt: not reported - Current portion of debt: not reported - Short-term borrowings: not reported - Shareholders' equity: us-gaap:StockholdersEquity ## Cash flow | Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | period not labelled (2025-03-31) | Q4 FY2025 (2025-06-30) | Q3 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Operating cash flow | $m | [11.2](/filings/0001558370-24-014247.md) | [7.5 d](/filings/0001558370-25-000601.md) | [12.3 d](/filings/0001558370-25-006267.md) | [14.3 d](/filings/0001104659-26-100081.md) | [12.0](/filings/0001104659-25-105434.md) | [13.5 d](/filings/0001104659-26-009130.md) | [13.4 d](/filings/0001104659-26-055383.md) | [14.6 d](/filings/0001104659-26-100081.md) | [11.6](/filings/0001104659-25-105434.md) | [15.1 d](/filings/0001104659-26-009130.md) | [16.8 d](/filings/0001104659-26-055383.md) | [17.7 d](/filings/0001104659-26-100081.md) | | Capital expenditure | $m | [0.3](/filings/0001558370-24-014247.md) | [0.4 d](/filings/0001558370-25-000601.md) | [0.4 d](/filings/0001558370-25-006267.md) | [0.6 d](/filings/0001104659-26-100081.md) | [0.7](/filings/0001104659-25-105434.md) | [1.1 d](/filings/0001104659-26-009130.md) | [0.1 d](/filings/0001104659-26-055383.md) | [0.2 d](/filings/0001104659-26-100081.md) | [0.2](/filings/0001104659-25-105434.md) | [0.6 d](/filings/0001104659-26-009130.md) | [0.7 d](/filings/0001104659-26-055383.md) | [0.4 d](/filings/0001104659-26-100081.md) | | Dividends paid | $m | [2.9](/filings/0001558370-24-014247.md) | [2.9 d](/filings/0001558370-25-000601.md) | [3.7 d](/filings/0001558370-25-006267.md) | [3.7 d](/filings/0001104659-26-100081.md) | not reported | not reported | [4.6 d](/filings/0001104659-26-055383.md) | [4.5 d](/filings/0001104659-26-100081.md) | [5.0](/filings/0001104659-25-105434.md) | [5.0 d](/filings/0001104659-26-009130.md) | [5.0 d](/filings/0001104659-26-055383.md) | [5.4 d](/filings/0001104659-26-100081.md) | | Share repurchases | $m | not reported | not reported | not reported | not reported | [7.3](/filings/0001104659-25-105434.md) | [10.7 d](/filings/0001104659-26-009130.md) | [18.8 d](/filings/0001104659-26-055383.md) | [0.0 d](/filings/0001104659-26-100081.md) | not reported | not reported | not reported | not reported | - Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities - Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment - Dividends paid: us-gaap:PaymentsOfDividends - Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock ## Shares | Line item | Unit | Q1 FY2023 (2022-09-30) | Q2 FY2023 (2022-12-31) | Q3 FY2023 (2023-03-31) | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | period not labelled (2025-03-31) | Q3 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Diluted shares (weighted) | millions of shares | [37.0](/filings/0001558370-23-018474.md) | [37.0](/filings/0001558370-24-000760.md) | [37.1](/filings/0001558370-24-006776.md) | [37.1](/filings/0001558370-24-014247.md) | [37.0](/filings/0001558370-25-000601.md) | [37.1](/filings/0001558370-25-006267.md) | [37.2](/filings/0001104659-25-105434.md) | [36.8](/filings/0001104659-26-009130.md) | [36.3](/filings/0001104659-26-055383.md) | [35.9](/filings/0001104659-25-105434.md) | [35.9](/filings/0001104659-26-009130.md) | [35.7](/filings/0001104659-26-055383.md) | - Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding Shares outstanding: 35,768,437 at 2026-08-21, from the cover of the [10-K filed 2026-08-24](/filings/0001104659-26-100081.md) (dei:EntityCommonStockSharesOutstanding). Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:19 ET. No prices; not investment advice.